We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Approximates Human Performance in Breast Cancer Diagnosis

By LabMedica International staff writers
Posted on 25 Jul 2016
Artificial intelligence (AI) methods that train computers to interpret pathology images could make pathologic diagnoses more accurate.

Researchers at Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) and Harvard Medical School (HMS; Boston, MA, USA) have developed a machine-learning algorithm that can be used for a range of applications, including speech and image recognition. More...
The algorithm teaches machines to interpret complex patterns and structures observed in real-life data by building multi-layer artificial neural networks, in a process which is thought to show similarities with the learning process occurring in the neurons of the neocortex, the region where thinking occurs.

The researchers trained the computer to distinguish between cancerous tumor regions and normal regions, based on a deep multilayer convolutional network that began with hundreds of training slides for which a pathologist has labeled regions of cancer and regions of normal cells. They then extracted millions of small training examples and used deep learning to build a computational model to classify them. The researchers then identified the specific training examples for which the computer was prone to making mistakes, and re-trained it using greater numbers of the more difficult training examples, gradually improving the computer’s performance.

The computers performance was tested in a competition at the 2016 International Symposium of Biomedical Imaging (ISBI), held during April in Prague (Czech Republic). The competition involved examining images of lymph nodes to decide whether or not they contained breast cancer. The computer algorithm identified correctly 92% percent of the time, nearly matching the 96% success rate of a human pathologist. The algorithm placed first in two separate categories, competing against private companies and academic research institutions from around the world. A technical report describing the approach was posted on June 18, 2016, on the arXiv.org repository.

“Peering into the microscope to sift through millions of normal cells to identify just a few malignant cells can prove extremely laborious using conventional methods. We thought this was a task that the computer could be quite good at,” said pathologist Andrew Beck, MD, PhD, director of bioinformatics at the Cancer Research Institute at BIDMC. “But the truly exciting thing was when we combined the pathologist’s analysis with our automated computational diagnostic method, the result improved to 99.5% accuracy. Combining these two methods yielded a major reduction in errors.”

“When we started this challenge, we expected some interesting results. The fact that computers had almost comparable performance to humans is way beyond what I had anticipated,” said Jeroen van der Laak, PhD, of Radboud University Medical Center (The Netherlands), an organizer for the competition. “It is a clear indication that artificial intelligence is going to shape the way we deal with histopathological images in the years to come.”

Related Links:
Beth Israel Deaconess Medical Center
Harvard Medical School

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.